Phexxi costs roughly $435 for a box of 12 prefilled applicators at retail pharmacy prices, which works out to about $36 per use. That makes it one of the most expensive on-demand contraceptives available, especially compared to over-the-counter spermicides at around $1 per use or condoms at under $1. Several factors drive this price, and most of them have less to do with what’s inside the tube than with the business realities surrounding it.
The Ingredients Are Simple, but the Product Isn’t
Phexxi’s active ingredients are lactic acid, citric acid, and potassium bitartrate (cream of tartar). These are common, inexpensive, food-grade substances classified as Generally Recognized as Safe by the FDA. The gel base is similarly basic: alginic acid, xanthan gum, glycerin, and purified water. An FDA review of the manufacturing process described it as “straightforward and robust,” and the prefilled vaginal applicator was classified as a “technologically simplistic device.” In other words, neither the raw materials nor the manufacturing process explain the price tag.
What does start to explain it is the regulatory path the product had to travel. Phexxi is classified as a drug-device combination product, meaning it went through a full FDA new drug application process. That required years of clinical development, including a large Phase 3 trial called AMPOWER, which wrapped up in late 2018. The cost of designing, running, and analyzing that trial, plus a Phase 2b study and all the supporting regulatory work, had to be recouped by the company that brought Phexxi to market.
A Small Company With Big Overhead
Phexxi is made by Evofem Biosciences, a small pharmaceutical company with a limited product portfolio. Unlike large drugmakers that can spread their fixed costs across dozens of products, Evofem has relied heavily on Phexxi as its primary revenue source. That means the price of every box has to help cover not just manufacturing but also corporate operations, regulatory compliance, and investor expectations.
Marketing is a significant piece of that overhead. Evofem spent $9.2 million on selling and marketing in 2024 alone, down from $11.7 million in 2023. For a product with relatively modest sales volume, those costs get baked directly into the per-unit price. Phexxi occupies a niche market: it’s a hormone-free, on-demand prescription contraceptive, which appeals to a specific group of patients but limits the total customer base. Low volume and high fixed costs are a reliable recipe for expensive products.
No Generic Competition Until 2033
One of the biggest reasons Phexxi stays expensive is the absence of any generic alternative. The last qualifying patent on Phexxi doesn’t expire until March 2033, according to FDA records. Until then, no other company can manufacture and sell a generic version, so there’s no competitive pressure to lower the price. This is a common dynamic in pharmaceuticals: brand-name drugs without generic rivals can maintain high prices because patients and insurers have no cheaper equivalent to switch to.
Even after patents expire, a generic vaginal gel combination product would still need to go through its own regulatory approval process, which could add additional years before a lower-cost option actually reaches pharmacy shelves.
Insurance Coverage Is Inconsistent
Under the Affordable Care Act, most non-grandfathered health insurance plans are required to cover FDA-approved contraceptives without cost sharing. The federal guidelines from the Health Resources and Services Administration specifically recommend coverage of “the full range of FDA-approved, -granted, or -cleared contraceptives.” In theory, that includes Phexxi.
In practice, coverage varies significantly. Some insurers cover Phexxi with no out-of-pocket cost, while others place it on higher-cost tiers, require prior authorization, or steer patients toward a preferred alternative in the same contraceptive category. If your plan considers an over-the-counter spermicide to be a “reasonable alternative” in the same class, it may not cover Phexxi at zero cost. Religious and moral exemptions also allow certain employers and plans to opt out of contraceptive coverage entirely. The result is that many patients end up paying some or all of the retail price themselves.
Evofem offers a copay card for patients with commercial insurance, which can reduce out-of-pocket costs. You can check eligibility through the program website or by calling 855-358-6583. Discount services like GoodRx can also bring the price down to around $374 per box, though that’s still substantial.
How It Compares to Other Options
The cost gap between Phexxi and other on-demand contraceptives is stark. A box of 10 prefilled spermicide applicators containing nonoxynol-9 costs about $11, or roughly $1 per use. Condoms run $0.25 to $0.50 each and are often available free at clinics and family planning organizations. Even at a discounted price of $374, Phexxi comes to over $31 per use.
The clinical case for Phexxi rests on it being hormone-free, not containing nonoxynol-9 (which can cause irritation and increase infection risk with frequent use), and working through a different mechanism: it maintains the vagina’s naturally acidic pH, which impairs sperm motility. For people who want or need a non-hormonal option and have had problems with spermicides, Phexxi fills a gap that other products don’t. But filling a gap in a small market with patent protection and no generic competition is precisely the combination that keeps prices high.
If your insurance covers Phexxi fully, the cost question is largely academic. If you’re paying out of pocket, the math is worth doing carefully. At roughly $36 per use at retail, annual costs can add up quickly depending on how frequently you use it, and the manufacturer savings programs or pharmacy discount cards are worth exploring before filling a prescription.